Novel Approaches for Characterizing Exposure and Response to Engineered Nanomaterials (R43 Clinical Trials Not Allowed)
The summary for the Novel Approaches for Characterizing Exposure and Response to Engineered Nanomaterials (R43 Clinical Trials Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Approaches for Characterizing Exposure and Response to Engineered Nanomaterials (R43 Clinical Trials Not Allowed): This Funding Opportunity Announcement (FOA) solicits Phase I (R43) Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop and/or adapt novel technologies to enable the characterization of human exposures to engineered nanomaterials (ENMs) and to monitor or assess ENMs in diverse media ranging from biological samples to air and water.
Federal Grant Title: | Novel Approaches for Characterizing Exposure and Response to Engineered Nanomaterials (R43 Clinical Trials Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Environment Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-ES-18-008 |
Type of Funding: | Grant |
CFDA Numbers: | 93.113 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | September 11th, 2018 |
Original Application Deadline: | September 11th, 2018 |
Posted Date: | July 3rd, 2018 |
Creation Date: | July 3rd, 2018 |
Archive Date: | October 17th, 2018 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | July 3rd, 2018 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. see the funding opportunity for eligibility details
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-18-008.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clini...
- • Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic ...
- • Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clini...
- • Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
- • Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...
- • Outstanding New Environmental Scientist Award (ONES)
- • Environmental Health Sciences Core Center Grants
- • Leiomyomata Uteri: Basic Science and Translational Research
- More Grants from the National Institutes of Health
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...